Category: Prohost Letters
In the Limelight
The Week in Review #18 The Market - The stock market recuperated most of its losses while analysts preferred to abstain from forecasting and remain bystanders during the market volatility. Although the causes of volatility have yet to be delineated,...
Read More
February 19, 2018
0
The Prohost Portfolio: Updating the Stock Targets
Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we believe have solid scientific fundamentals and dedicated managements. All the firms in the portfolio, except a few, have proprietary technologies, which enable the firms’...
Read More
March 15, 2018
0
Observing Queer Stories
Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an important factor Xa inhibitor Bevyxxa (betrixa-ban for extended prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for a...
Read More
March 2, 2018
0
What Are We Experiencing Now?
Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing and the good economy and the employment gains are the least utilized factors after being the most influential on the stock market performance. We...
Read More
October 4, 2019
0
During the Departed Week
The Week in Review #42 During the Departed Week The week started with the market losing over 1000 points and ended recuperating a large extent of the losses. Desperate during the market’s plummeting, some investors were happy for the rebound...
Read More
October 7, 2019
0
Prohost Letter #430
Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary endpoints? How did the drugs respond as compared to placebo; what is the disability index, clinical remission, disease activity rate and safety results? What’s...
Read More
April 5, 2019
0
The Week in Review #40
Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' ( GILD ) announcement at EASL? What is Gilead doing to find effective treatments for NASH? Why would Novo Nordisk's ( NVO ) anti-diabetes GLP-1 receptor drug...
Read More
April 16, 2019
0
This Past Week
The Week in Review #43 This Past Week After hearing hints about the trade war between China and the United States being avoided the market reversed course from faltering to flying at the speed of light. This trade war replaced...
Read More
October 22, 2019
0
An Approval & a Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio
The Week in Review #22 What Went Right or Wrong in the Biotech Sector During the Departing Week? - A lot happened in the biotech sector during the week, which departed at midnight. Topping the list of the week’s events...
Read More
May 7, 2018
0
The Biotech Revolution is Alive and Speeding
The Week in Review #21 Part 1 THE MARKET - Like symphonic orchestras that bring to the listeners’ ears, minds and souls melodies composed by legendary authors, the stock market reflects what’s going on in the world, which would positively or negatively...
Read More
April 24, 2018
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)